



国内版

国际版

In-vitro proliferation assay with recycled ascitic cancer cells in



All

Images

Videos

关闭取词

27,100 Results

Any time ▾

Inhibition of c-Src expression and activation in malignant ...

<https://mct.aacrjournals.org/content/6/7/1962> ▾

Jul 01, 2007 · **Malignant pleural mesothelioma (MPM)** is a deadly disease with few systemic treatment options. One potential therapeutic target, the non-receptor **tyrosine kinase c-Src**, causes changes in **proliferation, motility, invasion, survival, and angiogenesis in cancer cells** and may be a valid therapeutic target in **MPM**.

Cited by: 123 Author: Anne S. Tsao, Dandan He, Babita Saigal, ...

Publish Year: 2007

Malignant pleural fluid from mesothelioma has potent ...

<https://onlinelibrary.wiley.com/doi/full/10.1111/resp.12874>

In vitro cell proliferation assay. **Proliferation of mesothelioma cells** grown in vitro was assessed by three techniques: **trypan blue exclusion test of cell viability**, **8 methylene blue proliferation assay** 9 and **crystal violet colony formation assay**. 10 Cells were serum-starved for 24 h before **assays** were performed. Cells grown in the same standard DMEM with either 10% or 0% FCS served as controls.

Cited by: 8 Author: Hui Min Cheah, Sally M. Lansley, Julius F...

Publish Year: 2017

Antitumor activity of MEK and PI3K inhibitors against ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3582904>

Hamaguchi N, Hamada H, Miyoshi S, Irifune K, Ito R, Miyazaki T, Higaki J. In vitro and in vivo therapeutic efficacy of the **PPAR-γ agonist troglitazone** in combination with **cisplatin** against **malignant pleural mesothelioma cell growth**. *Cancer Sci.* 2010; 101:1955–1964.

Cited by: 8 Author: Seigo Miyoshi, Hironobu Hamada, Naohik...

Publish Year: 2012

Inhibition of mesothelioma cell growth in vitro by ...

<https://www.sciencedirect.com/science/article/pii/S0022214301298692>

In summary, **malignant mesothelioma** produces profound **morbidity and mortality** that is largely refractory to conventional **treatment modalities**. Our studies suggest that DC, a widely used and well-tolerated **antibiotic**, can substantially **inhibit mesothelioma cell growth in vitro** at concentrations achievable in **serum** with typical oral doses.

Cited by: 26 Author: Jeffrey B. Rubins, Darlene Charboneau, ...

Publish Year: 2001

Match Overview

1	Internet 26 words crawled on 05-Apr-2016 erj.ersjournals.com	2%
2	Crossref 16 words Kazuki Yamashita, Atsushi Urakami, Tadahiko Kubozoe, M asaharu Ikeda et al. "In vitro detection of cross-resistant an	1%
3	Internet 13 words crawled on 20-Sep-2014 effiloop.com	1%
4	Crossref 12 words Soon-Ah Park. "F-18 FDG PET/CT Evaluation of Sacrococcy geal Chordoma", Clinical Nuclear Medicine, 12/2008	1%
5	Crossref 12 words Kazuhiro Kitajima, Hiroshi Doi, Kozo Kuribayashi, Masaki H ashimoto et al. "Prognostic value of pretreatment volume-b	1%
6	Internet 10 words crawled on 18-Jun-2018 springerplus.springeropen.com	1%
7	Crossref 10 words Masahiro Ogasawara, Mamiko Miyashita, Michio Iida, Taka shi Fukuhara. "Immunological Analysis and Generation of	1%

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 50783

Manuscript Type: CASE REPORT

In-vitro proliferation assay with recycled ascitic cancer cells in malignant pleural mesothelioma

Takashi Anayama, Mai Taguchi, Takehiro Tatenuma, Hironobu Okada, Ryohei Miyazaki, Kentaro Hirohashi, Motohiko Kume, Keisuke Matsusaki, Kazumasa Orihiashi

Abstract

BACKGROUND

We report the first case, to our knowledge, of massive ascites due to recurrent malionant pleural mesothelioma that was controlled using KM-cell-free and



All

Images

Videos

关闭取词

27,100 Results

Any time ▼

Inhibition of c-Src expression and activation in malignant ...

<https://mct.aacrjournals.org/content/6/7/1962> ▼

Jul 01, 2007 - **Malignant pleural mesothelioma (MPM)** is a deadly disease with few systemic treatment options. One potential therapeutic target, the non-receptor **tyrosine kinase c-Src**, causes changes in **proliferation, motility, invasion, survival, and angiogenesis in cancer cells** and may be a valid therapeutic target in **MPM**.

Cited by: 123

Author: Anne S. Tsao, Dandan He, Babita Saigal, ...

Publish Year: 2007

Malignant pleural fluid from mesothelioma has potent ...

<https://onlinelibrary.wiley.com/doi/full/10.1111/resp.12874>

In vitro cell proliferation assay. **Proliferation of mesothelioma cells** grown in vitro was assessed by three techniques: **trypan blue exclusion test of cell viability, 8 methylene blue proliferation assay** 9 and **crystal violet colony formation assay**. 10 Cells were serum-starved for 24 h before assays were performed. Cells grown in the same standard DMEM with either 10% or 0% FCS served as controls.

Cited by: 8

Author: Hui Min Cheah, Sally M. Lansley, Julius F...

Publish Year: 2017

Antitumor activity of MEK and PI3K inhibitors against ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3582904>

Hamaguchi N, Hamada H, Miyoshi S, Irifune K, Ito R, Miyazaki T, Higaki J. In vitro and in vivo therapeutic efficacy of the **PPAR-γ agonist troglitazone** in combination with **cisplatin** against **malignant pleural mesothelioma cell growth**. Cancer Sci. 2010; 101:1955–1964.

Cited by: 8

Author: Seigo Miyoshi, Hironobu Hamada, Naohik...

Publish Year: 2012

Inhibition of mesothelioma cell growth in vitro by ...

<https://www.sciencedirect.com/science/article/pii/S0022214301298692>

In summary, **malignant mesothelioma** produces profound morbidity and mortality that is largely refractory to conventional treatment modalities. Our studies suggest that DC, a widely used and well-tolerated **antibiotic**, can substantially **inhibit mesothelioma cell growth in vitro** at concentrations achievable in serum with typical oral doses.

Cited by: 26

Author: Jeffrey B. Rubins, Darlene Charboneau, ...

Publish Year: 2001